Wednesday, November 03, 2021 8:30:54 AM
Literature Database
Use of CytoSorb in a patient with SARS-CoV-2 infection and secondary septic shock with multiple organ failure
Dr. Tobias Hübner, Dr. Stefanie Wick, PD Dr. Thomas A. Neff | Department for Anesthesia and Intensive Care Medicine, Münsterlingen Cantonal Hospital, Switzerland
11/03/2021
New!Reduction in catecholaminesSafetyAnticoagulation CitrateCase of the weekCase reportCOVID-19Critical CareCRRT pre filterInflammatory parameters
Download documentDownload document
Summary
CoW 44/2021 – This case reports on a 67-year-old male patient who was transferred from the emergency department to the multidisciplinary intensive care unit due to severe respiratory failure from a newly diagnosed COVID-19 disease.
Case presentation
Previously, the patient had been admitted as an emergency case by his son-in-law due to increasing dyspnea, fever and cough. The patient had not been vaccinated against COVID-19 and had returned the previous day from a trip abroad via a car journey of several hours, during which his condition increasingly deteriorated. The symptoms had been present for about 10 days, and the patient had already seen a doctor and received antibiotics during his stay abroad
Known medical history included hypertensive heart disease, chronic recurrent pancreatitis, post cholecystectomy and direct closure of an umbilical hernia for porcelain gallbladder (2020), sublay plastic mesh for recurrent umbilical hernia (2020)
He was immediately started on non-invasive ventilation therapy (NIV), however, this did not result in stabilization of his respiratory situation, so that endotracheal intubation was performed on the second day of hospitalization due to imminent respiratory exhaustion
Because of the bilateral pulmonary infiltrates and severely impaired gas exchange with an oxygenation index of <100 mmHg, the diagnosis of severe acute respiratory distress syndrome (ARDS) was made according to the Berlin definition followed by initiation of lung protective ventilation
In addition, Nitric Oxide therapy was established, which significantly improved his oxygenation (responder)
According to the current recommendations, immunomodulatory therapy with dexamethasone was started and continued for a total of 14 days
Initially, he had acute renal insufficiency, which was identified as prerenal and caused by the SARS-CoV-2 infection. Under volume therapy, renal retention parameters initially regressed
Five days after transfer to the ICU, the patient then developed septic shock with confirmation of Pseudomonas aeruginosa and Serratia marcescens in the tracheal tract
Empirical antibiotic therapy with piperacillin/tazobactam was started and escalated to meropenem and vancomycin after obtaining the resistance profile
In the meantime, he also developed acute tachycardic atrial fibrillation with frequencies up to 180/min. Despite various attempts at medication and electrical conversion, permanent sinus rhythm could not be sustained. This was later achieved by administering digoxin and subsequent additional amiodarone
In addition, high-dose volume resuscitation together with maximum vasoactive therapy (norepinephrine 1.5 µg/kg/min, epinephrine 0.5 µg/kg/min, vasopressin 0.03 E/min) and supplementary hydrocortisone (200mg/24h) were necessary to hemodynamically stabilize the patient
Furthermore, the patient developed sepsis-induced thrombocytopenia
In the context of the septic shock, the patient developed acute kidney failure (according to AKIN II) and again, severe metabolic acidosis, so that the indication for continuous renal replacement therapy (CRRT) was given
With the rationale to control the hyperinflammation (interleukin IL-6 129,367 pg/ml, procalcitonin PCT 85.9 ng/ml, C-Reactive Protein CRP 515 mg/l, leukocytes 24/µl) as well as treating lactic acidosis (4.7 mmol/l), CytoSorb hemoadsorption therapy was also started
Treatment
A total of 5 treatments with CytoSorb were performed for a total treatment period of 48 hours
The adsorber was operated in combination with a conventional CRRT machine (Multifiltrate, Fresenius Medical Care) run in CVVHD mode
Blood flow rate: 160 ml/min
Anticoagulation: citrate (4 mmol/h)
CytoSorb adsorber Position: pre-hemofilter
Measurements
Hemodynamic stability (need for vasoactive substances)
Inflammatory parameters (IL-6, PCT, CRP, leukocytes)
Lactate
Results
During the treatments and over the following 48 hours, there was a clear stabilization in his hemodynamic situation accompanied by a steady reduction in vasoactive therapy (noradrenaline 0.5 µg/kg/min, adrenaline stopped, vasopressin 0.01 E/min)
Control of the hyperinflammatory state was also achieved over the 5 treatments. IL-6 decreased from 129,367 pg/ml to 121 pg/ml, PCT from 85 to 25 ng/ml and CRP was reduced from 515 to 155 mg/l
The lactate values had returned to normal after the 5 treatments
Patient Follow-Up
At the neurological wake-up test 7 days after discontinuation of CytoSorb therapy, the patient showed no reaction at all, and his pupils remained for the first time unresponsive to light
An EEG performed the following day showed a severe general change (“alpha coma”) without relevant cortical activity, even under maximum stimulation, compatible with hypoxic brain damage without hope for recovery
Given this as well as a simultaneous recurrence of refractory cardiovascular and pulmonary failure, the decision was made in consultation with the family to discontinue life-sustaining therapies and the patient eventually died in the setting of hypoxia in COVID-19-induced ARDS
Conclusion
In this patient with SARS-CoV-2 infection and secondary septic shock with multiple organ failure, the use of CytoSorb resulted in significant hemodynamic stabilization, control of the hyperinflammation as well as resolution of his metabolic acidosis
This case shows that the early and individualized use of CytoSorb may significantly improve the hemodynamic situation. Unfortunately, the fatal outcome of this case with severe SARS-CoV-2 disease was only able to be delayed by Cytosorb, not prevented
The use of CytoSorb therapy was easy, safe and the installation of the adsorber as well as the corresponding changes were possible without any problems.
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM